cp wire

CP Wire Articles

Autolus Therapeutics plc (“Autolus”) announced on 6/22/2018 the pricing of its initial public offering in the United States of 8,823,530 American Depositary Shares (“ADSs”) representing 8,823,530... read more

Fri, 06/22/18 - 09:41 am
CP Staff

Phelps Hospital has launched Dascena’s InSight algorithm house wide. InSight is a machine learning platform built for accurate sepsis onset predictions using only vital signs in the hospital’s EHR... read more

Thu, 06/21/18 - 05:19 pm
CP Staff

Servier and Taiho Pharmaceutical Co., Ltd. Announced on 6/21/2-18 clinical data from the pivotal Phase III trial (TAGS) for Lonsurf (trifluridine and tipiracil, TAS-102) which showed... read more

Thu, 06/21/18 - 09:53 am
CP Staff
  • Combination of local anesthetic bupivacaine and anti-inflam meloxicam
  • Applied directly to site of injury
  • Company expects to submit NDA in second half of 2018

... read more

Thu, 06/21/18 - 09:17 am

The vast majority of the laws are directed towards pharmacy benefits managers (PBMs). Most prohibit PBMs from placing limits on... read more

Wed, 06/20/18 - 02:44 pm
CP Staff

iTeos Therapeutics SA announced on 6/20/2018 the completion of an oversubscribed $75 million (€64 million) Series B financing led by MPM Capital, with participation from additional new investors... read more

Wed, 06/20/18 - 09:34 am

Genedrive plc announced on 6/20/2018 its receipt of a multi-partner grant award from the UK National Institute for Health Research’s Invention for Innovation programme, for the development and... read more

Wed, 06/20/18 - 09:18 am
  • ProscaVax is OncBioMune’s lead immunotherapy platform candidate
  • Ph I trials led to PSA reductions in 3/4 of patients

OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("... read more

Wed, 06/20/18 - 09:06 am

Caladrius Biosciences, Inc. (Nasdaq:CLBS) announced on 6/19/2018 that the U.S. Food and Drug Administration (“FDA”) has granted regenerative medicine... read more

Tue, 06/19/18 - 09:38 am

Crown Bioscience announced on 6/19/2018 that it has been selected by Pierre Fabre Research Institute as one of their partners to advance their immuno-oncology drug discovery pipeline.

... read more

Tue, 06/19/18 - 09:19 am

Earlier this year, the Department of Justice (DOJ) announced a new initiative to fight the opioid epidemic ravaging the nation – the creation of the Prescription Interdiction and... read more
Mon, 06/18/18 - 03:53 pm

Like everyone, people with type 2 diabetes and obesity suffer from depression and anxiety, but even more so. Researchers at Joslin Diabetes Center now have demonstrated a surprising potential... read more

Mon, 06/18/18 - 10:55 am

Translate Bio announced on 6/18/2018 that it has launched an initial public offering of 7,700,000 shares of its common stock. In addition, Translate Bio expects to grant the underwriters a 30-day... read more

Mon, 06/18/18 - 09:53 am

Parkinson’s Institute and Clinical Center (PICC) and Axial Biotherapeutics announced today a collaboration to investigate interventions targeting gastrointestinal (GI) metabolites that may cause... read more

Mon, 06/18/18 - 09:32 am
  • Early results in one group exceed initial therapeutic target
  • Patients (small number in Ph I currently) appear to remain stable for up to two years
  • LentiGlobin is being... read more
Fri, 06/15/18 - 09:51 am
  • One time treatment may address underlying cause of the disease
  • Works by inserting a functional human beta-globin gene into a patient’s own hematopoietic stem cells
  • ... read more
Fri, 06/15/18 - 09:32 am
  • Futility analysis found primary endpoint... read more

Fri, 06/15/18 - 08:54 am

Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSX:TRIL) announced on 6/14/2018 that it has initiated dosing in its phase 1 clinical trial of TTI-622 (SIRPaFc-IgG4), a checkpoint inhibitor of the... read more

Thu, 06/14/18 - 10:07 am
  • PXT3003 is in Ph III in the US and Europe
  • Granted orphan status in US and Europe
  • CMT is one of the most common inherited neurological disorders

Pharnext SA (... read more

Thu, 06/14/18 - 09:51 am

Verseon will be starting a first-in-human phase I trial in Australia for its lead-PROAC (PRecision Oral AntiCoagulant) VE-1902, which has successfully completed regulatory toxicology studies and... read more

Thu, 06/14/18 - 09:31 am


current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.